Introduction
Stem cell donor registries were founded when adult BM donor volunteers were the only source of hematopoietic stem cells (HSCs) for unrelated transplantation. The procedures and systems used by the registries were designed to conduct donor searches and facilitate the safe exchange of adult BM and later PBSCs. Since the first successful hematopoietic SCT using cord blood from a sibling in 1988 1 and the establishment of the first public umbilical cord blood banks (CBBs) in New York, USA 2 and Du¨sseldorf, Germany in the early 90s, cryopreserved cord blood cells became a third source of stem cells. Thirty-two stem cell donor registries have expanded their services and now also provide cord blood products. Some registries have collaboration with a single CBB; others have a network of several CBBs. As the World Marrow Donor Association (WMDA) documentation only covered the international exchange of BM and PBSC, the Cord Blood Working Group (CBWG) was initially established in 2007 to gather and share information about a range of cord blood issues.
Thus, the early work of the CBWG involved surveys and discussions to understand the current practices of registries already involved in facilitating the international exchange of cord blood units (CBUs). More recently, the work has focused on the standardization of the CBU-associated documentation and services provided by registries and CBBs, especially around the specific processes and procedures related to exchange of CBUs. This CBWG has also worked closely with Eurocord to provide some initial recommendations for the search and selection of CBUs for transplantation. This paper provides information about the aims and activities of this recently established working group and describes some of the most relevant operational and regulatory issues involved in the provision of CBUs.
CBBs and cord blood registries
There are 131 voluntary CBBs established in 35 countries. These CBBs are variously run by hospitals, blood banks or free-standing organizations. The main aim of a CBB is to collect voluntarily donated cord blood to be used for any patient who may need an unrelated hematopoietic SCT. The number of CBUs available for transplantation increased 10 fold from 44 000 in 1999 to 452 000 in 2008 ( Figure 1 ) with an associated increase in the use of cord blood products from 3 in 1993 to 3529 in 2008 ( Figure 2) .
The main aspects of CBBs are to collect, process, test, bank, select and release CBUs for transplantation. The majority of CBBs operate in close association with their national registry of volunteer adult donors and therefore those aspects related to the listing, selection, issue and transport of the CBUs are usually carried out by the registry. However, there are CBBs that operate independently and in those cases they need to establish their own procedures related to the registry activities. For example, when a CBU is released for registration in the international databases, a CBB can list their units directly in the international databases or have an established relationship with a registry. In all, 94 CBBs are associated with a registry, 11 CBBs list their units directly in the international databases and 26 CBBs only provide units locally. The WMDA Annual Report Cord Blood Registries/Banks reports the activities of 122 CBBs. In 2008, 729 CBUs were provided by independent CBBs, 733 CBUs were provided locally and 2067 CBUs were provided through a registry.
Facilitation of a CBU
There are fewer steps in the release of CBU than for HSC's from adult donors, because CBUs are fully tested and characterized at the time they are stored and listed for searches. The process is faster, because it does not require the donor work-up activities required for marrow and PBSC collection. Figure 3 shows the CBU search process with recommended time frames.
Once the CBUs are HLA typed and have been medically qualified, they can be listed for search. The stem cell donor registries and independent CBBs list the CBUs in a number of international databases. Bone Marrow Donor Worldwide lists 339 025 CBUs, the Netcord Foundation virtual office 83 759, the United States National Marrow Donor Program 93 767 and Asiacord lists 111 662 CBUs. It is known that at least 69 816 CBUs are not listed in international databases. Transplant centers have access to these databases to search for a cord blood unit. An initial search report contains information about the units that have the highest HLA match grade with the patient, usually cord blood units are typed at the Ag level for class I and at the allele level for DRB1 and these are sorted according to the reported total nucleated-cell count (TNC) before freezing. International recommendations from Eurocord and other centers advise a minimum of 2 Â 10 7 TNC/kg and 2 Â 10 5 CD34 þ cells/kg of recipient body weight. By contacting the registry and asking for a 'Cord Blood Unit Report' a transplant center can obtain detailed information about the CBU. This 'Cord Blood Unit Report' contains information about the gender and race of the donor, TNC, HLA typing, testing done on the mother and on the CBU, collection date, processing method, sample inventory and the type of bags used for cryopreserving the unit. This first interaction between the Transplant Centre and the Registry/CBB is called a preliminary search.
Based on the information shown on the Cord Blood Unit Report, the Transplant Centre decides whether to move to the next step in the process, called 'formal search'. Formal search means that the transplant center asks for further HLA typing of the unit and may also request additional local infectious disease markers, such as human Tlymphotropic virus and West-Nile virus, to be carried out from maternal blood samples.
When a transplant center orders a unit, the shipment date is agreed between the transplant center, the registry and the CBB. Although CBUs can be shipped within a day or two for emergency orders, most CBBs prefer at least three to five days notice. CBBs that carry out additional pre-release viability or potency tests such as colony forming units may require up to 15 days notice. CBUs are transported in a dry shipper, which holds the CBU in vapour-phase liquid nitrogen. The dry shipper is collected from the CBB by a courier company trained in international shipping and may not be irradiated for inspection.
Units are ordered before the patient undergoes conditioning for the transplant procedure to ensure that the shipment has been successful. The transplant center is responsible for checking the accompanying unit records when the unit arrives, unloading the shipper, checking the integrity of the unit and placing it in a liquid nitrogen freezer for temporary storage until the transplant date. The dry shipper is returned to the CBB for inspection for any damage and to read the data from the continuous temperature monitor to assure that the desired temperature during shipment was maintained. One of the advantages of a CB donor is that because the units are sent frozen, the transplant center can have the unit before conditioning the patient.
After the release of a CBU, CBBs are required to collect outcome data to fulfill regulatory or accreditation requirements. The WMDA supports the systematic collection of these data, as complete clinical information on the outcome 
Advantages of a relationship between CBB and a registry
Over 70% of the CBBs have established a relationship with a registry, which oversees the facilitation of the CBU. Registries have a long experience in the international exchange of BM and PBSC products that benefits CBBs. Over 40% of the CBUs is exported to another country, in 2008 1235 CBUs were provided internationally. Registries have the infrastructure to list cord blood units in the international databases, like Bone Marrow Donors Worldwide. In addition, registries have systems in place to coordinate data transactions including demographic, clinical and genetic information and lab samples and results for CBUs. One of the most complicated components is creating and maintaining the matching algorithm for patient searches, which requires HLA expertise. This specific knowledge in described elsewhere in this issue.
Registries also offer knowledge of import and export requirements per country. As regulations differ from country to country, excellent communication and cooperation is essential to ensure that all appropriate donor screening questions and infectious disease tests have been carried out according to the importing country's requirements. The WMDA has a system in place to exchange this critical information.
Cord blood banks have a maternal health questionnaire to screen donors with questions covering risk factors for infectious diseases such as the HIV and hepatitis B. In all, 8 of the 42 participating Cord Blood Registries do not cover risks for Creutzfeldt-Jakob disease, 3 do not cover malaria transmission and 1 does not cover genetic disease in the donor family.
The type of tests carried out varies between the different CBBs based on their national regulations. International standards require that infectious disease testing be done on a maternal sample; usually it must be collected before or within seven days of delivery. Some countries require additional testing of the maternal donors to be done at 6 months after delivery. Other countries require that the tests also be performed on a sample of the CBU.
The timing of other tests on the CBUs varies between the CBBs. Most tests are done before the registration of a unit in the international database. However, some tests may be carried out before shipping. An example is hemoglobinopathy testing, which is not done before listing units by 18 of the 42 cord blood registries.
On the WMDA website (http://www.worldmarrow.org) information is provided by country on which tests are done on the mother at time of collection, tests carried out on the CBU before the unit is released, details about the mother's health questionnaire and export information, as some countries require a special permit.
The CBWG has discussed several challenges the past 2 years related to the differences in various processes required for CBU international exchange vs marrow and PBSC international exchange:
Listing in different databases
The national registries list their adult volunteer donors in one central database, Bone Marrow Donors Worldwide (see web site www.bmdw.org). CBUs may be listed by the individual CBB or by the national registry. The CBUs can be listed in more than one international database and searchers must be aware that duplicate listings are possible. There is an on-going effort by registries to identify Figure 3 Cord blood search process. A flow diagram of each step of the cord blood search process.
Cord blood banking, registry operations K Welte et al duplicate sources of information and to work with transplant centers to select the unit that best meets the patient's needs.
Standard terminology in the communication with the
One important accomplishment of the CBWG was to adopt a comprehensive standard CBU report that can be used by any CBB in the world. A report template is found on the WMDA web site. If the CBB has done additional testing a supplemental CBU Report Template is available on the WMDA web site (http://www.worldmarrow.org).
Mother's health questionnaire One of the activities of the CBWG was to gather information about diseases that CBBs should include in the maternal health questionnaire. A total of 18 cord blood registries noted which diseases from different categories would cause units to be excluded when they occurred in the baby's immediate relatives (Table 1) .
Limited contiguous segments
One unique aspect of CBUs is that there are limited additional samples available to carry out HLA typing when requested by a transplant center. The most valuable sample type is the small segment that is stored attached to the CBU, called a contiguous segment. This is the only sample type that can definitively assure that the HLA typing in the unit is what was reported for listing the CBU. The number of contiguous segments is limited (one to three small volume segments for a CBU). When all contiguous segments have been exhausted, the likelihood that the CBU will be ordered in future is low. Today, WMDA guidelines are in place about how attached segments should be used to provide the best information to transplant centers and protect the value of the CBU for the CBB.
The CBWG has defined two HLA typing categories: extended typing, which can be done on any CBU sample; and identity typing, which is performed from a contiguous segment. These results are reported to the transplant center and to the CBB. When there is only one segment for a unit, the segment generally stays with the unit when shipped. The final identity typing can then be carried out by the transplant center before the unit is thawed.
Older units may not have contiguous segments; thus, additional samples that are not attached to the CBU need to be used for HLA typing. Furthermore, other DNA based genetic markers (for example, STRs) should be considered to confirm the relationship of the samples to the CBU. Registries and CBBs should notify the transplant center when there is no segment available for testing. Questions asked by at least 80% of the respondents: Does your registry inquire if the mother has a history of abnormal prenatal testing? Does your registry inquire if the mother had any children die in childhood? Does your registry inquire if the mother had any stillborn children? Does your registry perform routine follow-up of the infant donor post donation?
develop a reservation form for transplant centers to clarify the timelines and the details of how to move from a formal search process to the final step of ordering a particular unit.
Selection of a cord blood donor
The selection of a unit is the responsibility of the transplant center. The best indicators of a CBU's content are cell counts measured post-processing, before cryopreservation and then before the release of the CBU on a segment. One of the areas where the CBWG has tried to gather and exchange information is around the factors that are involved in the selection of CBUs. Although, the specific requirements varied according to the transplant programmes, published data both in Europe and in the United States indicate the importance of TNC content per kilogram of patient weight in reduced-intensity and myeloablative conditioning stem cell transplants for both single and double cord blood transplantation. Also with regard to the HLA match status, it has been found that a 0-1 mismatch is preferable to a 2 mismatch and that 3-4 mismatches should be avoided for almost all patients. The third important factor is to identify whether the donor is selected for transplantation into a patient with malignant or non-malignant disease, as the effect of the TNC and HLA may differ. 3 
Transport of CBUs around the globe
The 56 cord blood registries participating in the WMDA annual report reported 44 transport incidents in 2008 (1.5% of the shipments). In 22 cases the CBU bag arrived at the transplant center cracked, torn or otherwise unusable because of transportation. Ten times the CBU arrived thawed, five times custom officers opened the dry shipper and seven times the courier delivered the dry shipper at the wrong address. The WMDA registries report serious transport problems to the WMDA Serious Product Events and Adverse Effects Registry, where the trends are monitored (for example, where a specific airport always opens the dry shipper). More information about Serious Product Events and Adverse Effects Registry can be found elsewhere in this issue.
The WMDA recommends that the temperature of the CBU is monitored with a continuous monitor device during the shipment of the CBU to assure that the unit temperature continues to be maintained at or below À150 1C to protect the unit from premature thawing. Use of the older minimum temperature single use indicators does not meet the current standards.
Quality of CBUs
An important aspect of the banking and shipping of CBUs for clinical use is the quality control monitoring of the unit in all phases of its collection, preservation, and shipment; the quality control measures are a requirement of Netcord-FACT accreditation. The quality, safety and efficiency of a CBU for clinical transplantation are a priority for the WMDA and the CBWG is approaching this issue in several ways. Complete clinical information on the outcome of the transplant provides important information about the quality of the CBU. The WMDA supports the systematic collection of recipient outcome data in a data collection registry (for example, Eurocord Registry, Center for International Blood and Marrow Transplant Research). The following information should be obtained to evaluate the processes: the number of TNC and CD34 þ , viability after thawing, method of thawing and adverse events at infusion.
A second parameter for quality of CBUs is whether a unit comes from an accredited cord blood registry or not. Three international organizations offer accreditation programs and actively collaborate to promote high quality CBUs; the WMDA, Netcord Foundation in collaboration with FACT and the American Association of Blood Banks. All these organizations are involved in the Alliance for Harmonisation of Cellular Therapy Accreditation and are working on setting harmonized standards on an international basis. Each accreditation program covers different aspects of unrelated cord blood transplantation. The main objective of the Netcord-FACT accreditation is to evaluate aspects of CBB including donor selection, methods of collection, processing, testing and storage of the units and release and transportation of the CBUs to the transplant centers. American Association of Blood Banks developed high-quality standards on the area of cord blood collection, storage and distribution. The WMDA Accreditation Program focuses on the registry operations. More detailed information about the WMDA Accreditation Program is described elsewhere in this issue.
These accreditation schemes address some different aspects of cord blood banking, listing and transplantation, and they all refer to each other for complementary requirements. For example, the WMDA Standards states 'If a Registry relies on an independent Donor Center or Cord Blood Bank to recruit and characterize donors, the Registry must ensure that the Donor Center/Cord Blood Bank complies with relevant WMDA standards'. In this case, requiring accreditation of the cord blood bank by an organization such as Netcord-FACT might be one means by which the registry ensures that this WMDA standard can be met. The Netcord-FACT standards describe the requirement in another way: 'If a CBB utilizes a registry to deliver services related to the listing, search and selection, reservation, and/or release of a CBU the registry should be accredited by the WMDA'. A list of accredited cord blood banks and cord blood registries can be found on the websites of the FACT Office (www.factwebsite.org), American Association of Blood Banks (www.aabb.org) and WMDA.
Historically, the policies and procedure to collect, process and store cord blood differed among CBBs. There also remain differences today in processes used by different CBBs and processes required by different countries. The development and implementation of international standards allows more CBBS to become accredited and for procedures to become more consistent across the world.
Challenges in the international exchange of CBUs and future directions for the cord blood-working group Although cord blood banking and cord blood transplantation have become more standardized, there are still a Another important challenge is the increasing number of private, usually for-profit CBBs storing autologous units that may wish to allow some units to be made available through a public allogeneic CBB. The CBWG has been discussing this issue with the Ethics Working Group and a public statement about these so-called hybrid CBB models is being completed. The CBWG developed a 'Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage' that describes three different CBB models: unrelated/public, related/directed and autologous/ private models. The statement is available on the WMDA web site.
Finally, the future clinical use of other cellular products derived from cord blood, such as MSCs or regulatory T cells will also be monitored to assess the need for the development of new guidelines or procedures.
